Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER – study)

References

• Gargiulo L, Ibba L, Malagoli P, et al. Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: a 104-week multicenter retrospective study – IL PSO (ITALIAN LANDSCAPE PSORIASIS). J Eur Acad Dermatol Venereol. 2023;37(5):1–8. doi:10.1111/jdv.18913.
   Web of Science ®Google Scholar
• Osuna CG, García SR, Martín JC, et al. Use of biological treatments in elderly patients with skin psoriasis in the real world. Life (Basel). 2021;11(12):1348. doi:10.3390/life11121348.
   PubMed Web of Science ®Google Scholar
• Phan C, Beneton N, Delaunay J, et al. Effectiveness and safety of anti-interleukin-17 therapies in elderly patients with psoriasis. Acta Derm Venereol. 2020;100(18):adv00316. doi:10.2340/00015555-3678.
   PubMedGoogle Scholar
• Sandhu VK, Ighani A, Fleming P, et al. Biologic treatment in elderly patients with psoriasis: a systematic review. J Cutan Med Surg. 2020;24(2):174–186. doi:10.1177/1203475419897578.
   PubMed Web of Science ®Google Scholar
• van Winden MEC, van der Schoot LS, van de L’Isle Arias M, et al. Effectiveness and safety of systemic therapy for psoriasis in older adults: a systematic review. JAMA Dermatol. 2020;156(11):1229–1239. doi:10.1001/jamadermatol.2020.2311.
   PubMed Web of Science ®Google Scholar
• Kwon HH, Kwon IH, Youn JI. Clinical study of psoriasis occurring over the age of 60 years: is elderly-onset psoriasis a distinct subtype? Int J Dermatol. 2012;51(1):53–58. doi:10.1111/j.1365-4632.2011.04979.x.
   PubMed Web of Science ®Google Scholar
• Di Caprio R, Caiazzo G, Cacciapuoti S, et al. Safety concerns with current treatments for psoriasis in the elderly. Expert Opin Drug Saf. 2020;19(4):523–531. doi:10.1080/14740338.2020.1728253.
   PubMed Web of Science ®Google Scholar
• Di Lernia V, Goldust M. An overview of the efficacy and safety of systemic treatments for psoriasis in the elderly. Expert Opin Biol Ther. 2018;18(8):897–903. doi:10.1080/14712598.2018.1504016.
   PubMed Web of Science ®Google Scholar
• Ricceri F, Bardazzi F, Chiricozzi A, et al. Elderly psoriatic patients under biological therapies: an Italian experience. J Eur Acad Dermatol Venereol. 2019;33(1):143–146. doi:10.1111/jdv.15139.
   PubMed Web of Science ®Google Scholar
• Ter Haar ELM, Ten Bruin EE, Bronkhorst EE, et al. Safety assessment of conventional and biological systemic therapy in older adults with psoriasis, a real-world multicentre cohort study. Acta Derm Venereol. 2022;102:adv00805. doi:10.2340/actadv.v102.2412.
   PubMed Web of Science ®Google Scholar
• Elm TH, Se T, Jmpa van den R, et al. Drug survival, safety, and effectiveness of biologics in older patients with psoriasis: a comparison with younger patients-a BioCAPTURE registry study. Drugs & Aging. 2022;39(9):715–727. doi:10.1007/s40266-022-00961-y.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650–661. doi:10.1016/S0140-6736(18)31713-6.
   PubMed Web of Science ®Google Scholar
• Megna M, Cinelli E, Gallo L, et al. Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period. Arch Dermatol Res. 2022;314(6):619–623. doi:10.1007/s00403-021-02200-7.
   PubMed Web of Science ®Google Scholar
• Galluzzo M, Tofani L, Lombardo P, et al. Use of guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1 year real-life study. J Clin Med. 2020;9(7):2170. doi:10.3390/jcm9072170.
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Fabbrocini G, Cinelli E, et al. Guselkumab and risankizumab for psoriasis: a 44-week indirect real-life comparison. J Am Acad Dermatol. 2021;85(4):1028–1030. doi:10.1016/j.jaad.2021.01.025.
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Fabbrocini G, Cinelli E, et al. Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti-interleukin-17 treatment: a real-life 52-week retrospective study. Dermatol Ther. 2021;34(1):e14673. doi:10.1111/dth.14673.
   PubMed Web of Science ®Google Scholar
• Santostefano M, Herzyk D, Montgomery D, et al. Nonclinical safety of tildrakizumab, a humanized anti–IL-23p19 monoclonal antibody, in nonhuman primates. Regul Toxicol Pharmacol. 2019;108:104476. doi:10.1016/j.yrtph.2019.104476.
   PubMed Web of Science ®Google Scholar
• Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390(10091):276–288. doi:10.1016/S0140-6736(17)31279-5.
   PubMed Web of Science ®Google Scholar
• Ter Haar ELM, Van den Reek JMPA, Gaarn Du Jardin K, et al. Efficacy and safety of tildrakizumab in older patients: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 244 weeks. Acta Derm Venereol. 2023;103:adv17752. doi:10.2340/actadv.v103.17752.
   PubMed Web of Science ®Google Scholar
• Kolli SS, Gabros SD, Pona A, et al. Tildrakizumab: a review of phase II and III clinical trials. Ann Pharmacother. 2019;53(4):413–418. doi:10.1177/1060028018809522.
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Fabbrocini G, Cinelli E, et al. Anti‐interleukin‐23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real‐world practice. Clin Exp Dermatol. 2022;47(3):561–567. doi:10.1111/ced.14979.
   PubMed Web of Science ®Google Scholar
• Campione E, Lambiase S, Gaeta Shumak R, et al. A real-life study on the use of tildrakizumab in psoriatic patients. Pharmaceuticals (Basel). 2023;16(4):526. doi:10.3390/ph16040526.
   PubMedGoogle Scholar
• Galluzzo M, Talamonti M, Cioni A, et al. Efficacy of tildrakizumab for the treatment of difficult-to-treat areas: scalp, nail, palmoplantar and genital psoriasis. J Clin Med. 2022;11(9):2631. doi:10.3390/jcm11092631.
   PubMed Web of Science ®Google Scholar
• Megna M, Tommasino N, Potestio L, et al. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study. J Dermatolog Treat. 2022;33(6):2813–2820. doi:10.1080/09546634.2022.2081655.
   PubMed Web of Science ®Google Scholar
• Narcisi A, Valenti M, Gargiulo L, et al. Real‐life effectiveness of tildrakizumab in chronic plaque psoriasis: a 52‐week multicentre retrospective study—IL PSO (Italian landscape psoriasis). J Eur Acad Dermatol Venereol. 2023;37(1):93–103. doi:10.1111/jdv.18594.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Fargnoli MC, Amerio P, et al. Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis. Ital J Dermatol Venerol. 2022;157:1–78. doi:10.23736/S2784-8671.21.07132-2.
   PubMedGoogle Scholar
• Tildrakizumab – Summary of Product Characteristics. https://www.ema.europa.eu/en/documents/product-information/ilumetri-epar-product-information_en.pdf.
   Google Scholar
• Blauvelt A, Chiricozzi A, Ehst BD, et al. Safety of IL-23 p19 inhibitors for the treatment of patients with moderate-to-severe plaque psoriasis: a narrative review. Adv Ther. 2023;40(8):3410–3433. doi:10.1007/s12325-023-02568-0.
   PubMed Web of Science ®Google Scholar
• Crowley JJ, Warren RB, Cather JC. Safety of selective IL-23p19 inhibitors for the treatment of psoriasis. J Eur Acad Dermatol Venereol. 2019;33(9):1676–1684. doi:10.1111/jdv.15653.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Papp KA, Griffiths CEM, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–417. doi:10.1016/j.jaad.2016.11.041.
   PubMed Web of Science ®Google Scholar
• Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418–431. doi:10.1016/j.jaad.2016.11.042.
   PubMed Web of Science ®Google Scholar
• Gargiulo L, Narcisi A, Ibba L, et al. Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (italian landscape psoriasis). Front Med (Lausanne). 2023;10:1243843. doi:10.3389/fmed.2023.1243843.
   PubMed Web of Science ®Google Scholar
• Langley RG, Tsai TF, Flavin S, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol. 2018;178(1):114–123. doi:10.1111/bjd.15750.
   PubMed Web of Science ®Google Scholar
• Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394(10201):831–839. doi:10.1016/S0140-6736(19)31773-8.
   PubMed Web of Science ®Google Scholar
• Strober B, Menter A, Leonardi C, et al. Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies. J Eur Acad Dermatol Venereol. 2020;34(12):2830–2838. doi:10.1111/jdv.16521.
   PubMed Web of Science ®Google Scholar
• Galluzzo M, Chiricozzi A, Cinotti E, et al. Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations. Expert Opin Biol Ther. 2022;22(3):367–376. doi:10.1080/14712598.2022.1988566.
   PubMed Web of Science ®Google Scholar
• Bassi M, Singh S. Impact of obesity on response to biologic therapies in patients with inflammatory bowel diseases. BioDrugs. 2022;36(2):197–203. doi:10.1007/s40259-022-00522-0.
   PubMed Web of Science ®Google Scholar
• Mourad A, Straube S, Armijo-Olivo S, et al. Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta-analysis. Br J Dermatol. 2019;181(3):450–458. doi:10.1111/bjd.17738.
   PubMed Web of Science ®Google Scholar
• Pirro F, Caldarola G, Chiricozzi A, et al. Impact of body mass index on the efficacy of biological therapies in patients with psoriasis: a real-world study. Clin Drug Investig. 2021;41(10):917–925. doi:10.1007/s40261-021-01080-z.
   PubMed Web of Science ®Google Scholar
• Fernandez AP, Dauden E, Gerdes S, et al. Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2. J Eur Acad Dermatol Venereol. 2022;36(10):1774–1783. doi:10.1111/jdv.18167.
   PubMed Web of Science ®Google Scholar
• Megna M, Camela E, Battista T, et al. Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients. Expert Opin Drug Saf. 2023;22(1):43–58. doi:10.1080/14740338.2023.2173171.
   PubMed Web of Science ®Google Scholar
• Orsini D, Gargiulo L, Ibba L, et al. Effectiveness of risankizumab in plaque psoriasis with involvement of difficult-to-treat areas: a real-world experience from two referral centers. J Dermatolog Treat. 2023;34(1):2220849. doi:10.1080/09546634.2023.2220849.
   PubMed Web of Science ®Google Scholar
• Fiorillo G, Ibba L, Gargiulo L, et al. Effectiveness and safety of anti-IL-23 and anti-IL-17 biological therapies for psoriasis in elderly patients: real-world experience from two Italian ­hospitals. J Eur Acad Dermatol Venereol. 2023;37(12):e1444–e1446. doi:10.1111/jdv.19355.
   PubMedGoogle Scholar